glp-1 pipeline news GLP‑1 real‑world data for obesity: A new standard for metabolic care GLP-1s like Ozempic are among
Description
Magnesium calms the nervous system
The Australia GLP-1 receptor agonist market size was valued at USD 570.49 million in 2025 and is expected to hit around USD 2,117.46 million by 2035, growing at a CAGR of 14.01% from 2026 to 2035.
Preclinical studies have confirmed that GIPRGLP1R coagonists improve several hallmarks of metabolic syndrome, such as obesity, hyperglycemia, and dyslipidemia
Moreover, to account for possible confounders, adjusted ORs (mainly based on age, sex, body mass index [BMI], diabetes) were pooled and analyzed
Why Hims is on solid legal ground to continue selling GLP-1s even after the shortage is over
Weve shown that Ros platform can help patients achieve outcomes consistent with clinical trials
